25 XP   0   0   10

Amylyx Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Amylyx together

PenkeI guess you are interested in Amylyx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amylyx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.

Quick analysis of Amylyx (30 sec.)










What can you expect buying and holding a share of Amylyx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.26
Expected worth in 1 year
$7.50
How sure are you?
38.5%

+ What do you gain per year?

Total Gains per Share
$1.24
Return On Investment
43.0%

For what price can you sell your share?

Current Price per Share
$2.88
Expected price per share
$2.7 - $11.82
How sure are you?
50%

1. Valuation of Amylyx (5 min.)




Live pricePrice per Share (EOD)

$2.88

Intrinsic Value Per Share

$5.95 - $7.70

Total Value Per Share

$12.21 - $13.97

2. Growth of Amylyx (5 min.)




Is Amylyx growing?

Current yearPrevious yearGrowGrow %
How rich?$433.4m$229.5m$168.1m42.3%

How much money is Amylyx making?

Current yearPrevious yearGrowGrow %
Making money$12.3m-$49.5m$61.9m502.6%
Net Profit Margin12.3%-3,944.1%--

How much money comes from the company's main activities?

3. Financial Health of Amylyx (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#134 / 1031

Most Revenue
#80 / 1031

Most Profit
#75 / 1031

Most Efficient
#111 / 1031

What can you expect buying and holding a share of Amylyx? (5 min.)

Welcome investor! Amylyx's management wants to use your money to grow the business. In return you get a share of Amylyx.

What can you expect buying and holding a share of Amylyx?

First you should know what it really means to hold a share of Amylyx. And how you can make/lose money.

Speculation

The Price per Share of Amylyx is $2.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amylyx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amylyx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.26. Based on the TTM, the Book Value Change Per Share is $0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $1.81 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amylyx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.072.4%0.186.1%-0.73-25.4%-0.28-9.7%-0.28-9.7%
Usd Book Value Change Per Share0.279.2%0.3110.8%1.8163.0%0.4816.7%0.4816.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.279.2%0.3110.8%1.8163.0%0.4816.7%0.4816.7%
Usd Price Per Share14.72-20.99-24.30-13.93-13.93-
Price to Earnings Ratio53.82-104.17--8.53-29.43-29.43-
Price-to-Total Gains Ratio55.53--117.57--12.82--65.20--65.20-
Price to Book Ratio2.35-3.80-7.75-3.55-3.55-
Price-to-Total Gains Ratio55.53--117.57--12.82--65.20--65.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.88
Number of shares347
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.310.48
Usd Total Gains Per Share0.310.48
Gains per Quarter (347 shares)107.46167.20
Gains per Year (347 shares)429.85668.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104304200669659
20860850013381328
3012901280020061997
4017191710026752666
5021492140033443335
6025792570040134004
7030093000046814673
8034393430053505342
9038693860060196011
10042994290066886680

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%4.08.00.033.3%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
Book Value Change Per Share3.01.00.075.0%5.05.02.041.7%5.06.02.038.5%5.06.02.038.5%5.06.02.038.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share3.01.00.075.0%5.05.02.041.7%5.06.02.038.5%5.06.02.038.5%5.06.02.038.5%

Fundamentals of Amylyx

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-08 21:04:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Amylyx Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Amylyx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Net Profit Margin of 4.4% means that $0.04 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 4.4%. The company is making a profit. +1
  • The TTM is 12.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ4.4%TTM12.3%-8.0%
TTM12.3%YOY-3,944.1%+3,956.5%
TTM12.3%5Y-1,834.4%+1,846.7%
5Y-1,834.4%10Y-1,834.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4%-171.8%+176.2%
TTM12.3%-205.8%+218.1%
YOY-3,944.1%-262.1%-3,682.0%
5Y-1,834.4%-455.6%-1,378.8%
10Y-1,834.4%-589.0%-1,245.4%
1.1.2. Return on Assets

Shows how efficient Amylyx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • 0.9% Return on Assets means that Amylyx generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.9%TTM2.7%-1.7%
TTM2.7%YOY-20.5%+23.2%
TTM2.7%5Y-33.5%+36.1%
5Y-33.5%10Y-33.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9%-12.5%+13.4%
TTM2.7%-12.2%+14.9%
YOY-20.5%-11.2%-9.3%
5Y-33.5%-13.4%-20.1%
10Y-33.5%-14.7%-18.8%
1.1.3. Return on Equity

Shows how efficient Amylyx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • 1.1% Return on Equity means Amylyx generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 1.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.1%TTM3.1%-2.0%
TTM3.1%YOY-24.4%+27.5%
TTM3.1%5Y-6.6%+9.6%
5Y-6.6%10Y-6.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1%-15.8%+16.9%
TTM3.1%-15.7%+18.8%
YOY-24.4%-13.9%-10.5%
5Y-6.6%-18.3%+11.7%
10Y-6.6%-19.2%+12.6%

1.2. Operating Efficiency of Amylyx Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Amylyx is operating .

  • Measures how much profit Amylyx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • An Operating Margin of 1.8% means the company generated $0.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 1.8%. The company is operating less efficient.
  • The TTM is 9.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM9.4%-7.6%
TTM9.4%YOY-4,013.5%+4,022.9%
TTM9.4%5Y-1,850.6%+1,860.0%
5Y-1,850.6%10Y-1,850.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-299.1%+300.9%
TTM9.4%-210.1%+219.5%
YOY-4,013.5%-279.7%-3,733.8%
5Y-1,850.6%-459.9%-1,390.7%
10Y-1,850.6%-596.9%-1,253.7%
1.2.2. Operating Ratio

Measures how efficient Amylyx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.98 means that the operating costs are $0.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.982. The company is less efficient in keeping operating costs low.
  • The TTM is 0.906. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.982TTM0.906+0.076
TTM0.906YOY40.633-39.728
TTM0.9065Y18.967-18.061
5Y18.96710Y18.9670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9822.861-1.879
TTM0.9063.193-2.287
YOY40.6333.615+37.018
5Y18.9675.560+13.407
10Y18.9677.396+11.571

1.3. Liquidity of Amylyx Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Amylyx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.66 means the company has $5.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 5.664. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.426. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.664TTM7.426-1.763
TTM7.426YOY7.749-0.322
TTM7.4265Y5.921+1.505
5Y5.92110Y5.9210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6643.986+1.678
TTM7.4264.440+2.986
YOY7.7495.552+2.197
5Y5.9216.158-0.237
10Y5.9216.492-0.571
1.3.2. Quick Ratio

Measures if Amylyx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Quick Ratio of 7.47 means the company can pay off $7.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 7.467. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.135. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.467TTM10.135-2.668
TTM10.135YOY11.928-1.793
TTM10.1355Y8.439+1.696
5Y8.43910Y8.4390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4673.638+3.829
TTM10.1354.168+5.967
YOY11.9285.515+6.413
5Y8.4396.012+2.427
10Y8.4396.209+2.230

1.4. Solvency of Amylyx Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Amylyx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amylyx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Amylyx assets are financed with 16.2% credit (debt) and the remaining percentage (100% - 16.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.162. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.137. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.162TTM0.137+0.025
TTM0.137YOY0.151-0.013
TTM0.1375Y1.748-1.611
5Y1.74810Y1.7480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1620.335-0.173
TTM0.1370.330-0.193
YOY0.1510.267-0.116
5Y1.7480.367+1.381
10Y1.7480.378+1.370
1.4.2. Debt to Equity Ratio

Measures if Amylyx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.4% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.194. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.160. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.194TTM0.160+0.034
TTM0.160YOY0.179-0.019
TTM0.1605Y0.104+0.056
5Y0.10410Y0.1040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1940.376-0.182
TTM0.1600.398-0.238
YOY0.1790.334-0.155
5Y0.1040.429-0.325
10Y0.1040.476-0.372

2. Market Valuation of Amylyx Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amylyx generates.

  • Above 15 is considered overpriced but always compare Amylyx to the Biotechnology industry mean.
  • A PE ratio of 53.82 means the investor is paying $53.82 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 10.531. Based on the earnings, the company is underpriced. +1
  • The MRQ is 53.824. Based on the earnings, the company is expensive. -2
  • The TTM is 104.170. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD10.531MRQ53.824-43.293
MRQ53.824TTM104.170-50.346
TTM104.170YOY-8.531+112.701
TTM104.1705Y29.427+74.743
5Y29.42710Y29.4270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.531-2.643+13.174
MRQ53.824-2.418+56.242
TTM104.170-2.742+106.912
YOY-8.531-4.123-4.408
5Y29.427-6.257+35.684
10Y29.427-6.478+35.905
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 3.776. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 19.298. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -22.688. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD3.776MRQ19.298-15.523
MRQ19.298TTM-22.688+41.986
TTM-22.688YOY-8.894-13.794
TTM-22.6885Y-9.717-12.970
5Y-9.71710Y-9.7170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.776-3.244+7.020
MRQ19.298-2.939+22.237
TTM-22.688-3.478-19.210
YOY-8.894-5.592-3.302
5Y-9.717-8.473-1.244
10Y-9.717-8.881-0.836
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Amylyx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.35 means the investor is paying $2.35 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 0.460. Based on the equity, the company is cheap. +2
  • The MRQ is 2.350. Based on the equity, the company is underpriced. +1
  • The TTM is 3.803. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.460MRQ2.350-1.890
MRQ2.350TTM3.803-1.453
TTM3.803YOY7.747-3.944
TTM3.8035Y3.554+0.249
5Y3.55410Y3.5540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4602.124-1.664
MRQ2.3502.041+0.309
TTM3.8032.118+1.685
YOY7.7472.915+4.832
5Y3.5543.682-0.128
10Y3.5544.114-0.560
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amylyx Pharmaceuticals Inc.

3.1. Institutions holding Amylyx Pharmaceuticals Inc

Institutions are holding 98.579% of the shares of Amylyx Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Vanguard Group Inc7.45050.002350500801241882.5211
2023-12-31BlackRock Inc5.90470.0015400233442687511.939
2023-12-31Viking Global Investors LP4.37070.1597296255500
2023-09-30Perceptive Advisors LLC3.96691.64232688873-2185046-44.8314
2023-09-30Stonepine Capital Management Llc3.711715.302525158681394840124.4251
2023-09-30Millennium Management LLC3.1270.0196211953519790410.2988
2023-09-30Boxer Capital LLC3.07462.0313208400000
2023-09-30Hudson Bay Capital Management LP2.0130.098313644461073546369.043
2023-12-31Franklin Resources Inc1.95480.00911325001707134114.4476
2023-09-30State Street Corporation1.8290.00131239753820547.0877
2023-09-30Citadel Advisors Llc1.81010.0048122694441361950.8553
2023-09-30Goldman Sachs Group Inc1.75140.00441187128-163350-12.0957
2023-09-30ING Investment Management LLC1.69040.027114578820824822.2122
2023-12-31Eventide Asset Management, LLC1.64770.2683111683700
2023-12-31Saturn V Capital Management LLC1.62186.1938109926821312524.0509
2023-12-31Jupiter Asset Management Limited1.56520.1548106090041116463.2817
2023-09-30Nuveen Asset Management, LLC1.47580.0065100035144727780.8711
2023-12-31Marshall Wace Asset Management Ltd1.45340.0246985114-212646-17.7536
2023-09-30Geode Capital Management, LLC1.44890.0021982068440714.6984
2023-09-30Morgan Stanley - Brokerage Accounts1.40470.0018952119-99727-9.4811
Total 53.272325.95636108962+3083276+8.5%

3.2. Funds holding Amylyx Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv2.5440.0019172436600
2024-01-31Vanguard Small Cap Index2.16190.0178146539040020.2738
2024-02-01iShares Russell 2000 ETF1.84880.03421253176-8282-0.6565
2023-09-30Eventide Healthcare & Life Sciences I1.64771.3116111683700
2024-01-31Franklin Biotechnology Discv A(acc)USD1.33020.821290165600
2024-01-31Vanguard Small Cap Growth Index Inv1.20440.04098163891500.0184
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.88490.015998202640.044
2023-12-31Fidelity Select Biotechnology0.87690.19025944156461712.1965
2023-12-31CREF Stock R10.76020.006451529000
2023-12-31Fidelity Small Cap Index0.75230.029550991960071.1921
2023-12-31American Century U.S. Small Cap Growth0.74280.23135035105035100
2023-12-31American Century Small Cap Growth Inv0.74280.23135035105035100
2023-12-31Jupiter Merian Glb Eq AbsRet I USD Acc0.70850.361548021218586563.1449
2024-01-31Franklin Biotechnology Discovery A0.65890.797446592262006.2323
2024-02-28iShares Russell 2000 Growth ETF0.65790.077244595520720.4668
2024-02-28iShares Biotechnology ETF0.56890.0973855913460.0898
2024-02-29SPDR® S&P Pharmaceuticals ETF0.56673.231838411800
2023-12-31Fidelity Series Small Cap Opps0.55090.1008373400-7000-1.8402
2024-01-31Emerald Growth A0.48230.577732693700
2024-01-31State St Russell Sm/Mid Cp® Indx NL Cl C0.44460.012630134900
Total 20.13568.181913648432+1281261+9.4%

3.3. Insider Transactions

Insiders are holding 14.259% of the shares of Amylyx Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-05James M FratesSELL179218.73
2024-03-05Joshua B CohenSELL413518.73
2024-03-05Gina MazzarielloSELL154018.73
2024-02-23Gina MazzarielloSELL283818.76
2024-01-09James M FratesSELL271616.33
2024-01-09Justin B KleeSELL584116.33
2024-01-09Patrick D YeramianSELL281216.33
2023-05-16James M FratesSELL3250026.94
2023-05-15Patrick D YeramianSELL1196529.03
2023-04-17Patrick D YeramianSELL4957930.54
2023-03-29Morningside Venture InvestmentSELL2904830.45
2023-03-27Morningside Venture InvestmentSELL6096430.5
2023-03-21Morningside Venture InvestmentSELL6344831.91
2023-03-16George M Milne JrSELL3500031.89
2023-03-16James M FratesSELL3250031.89
2023-03-16Justin B KleeSELL10000031.86
2023-03-16Morningside Venture InvestmentSELL912232.55
2023-03-16Patrick D YeramianSELL5462731.87
2023-03-14Morningside Venture InvestmentSELL7071434.54

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Amylyx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2650.310-14%1.814-85%0.482-45%0.482-45%
Book Value Per Share--6.2645.687+10%3.387+85%2.253+178%2.253+178%
Current Ratio--5.6647.426-24%7.749-27%5.921-4%5.921-4%
Debt To Asset Ratio--0.1620.137+18%0.151+8%1.748-91%1.748-91%
Debt To Equity Ratio--0.1940.160+21%0.179+8%0.104+86%0.104+86%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0680.176-61%-0.732+1170%-0.280+510%-0.280+510%
Free Cash Flow Per Share--0.1910.039+392%-0.673+453%-0.291+252%-0.291+252%
Free Cash Flow To Equity Per Share--0.1940.051+277%1.656-88%0.611-68%0.611-68%
Gross Profit Margin--1.0001.0000%1.091-8%1.028-3%1.028-3%
Intrinsic Value_10Y_max--7.705--------
Intrinsic Value_10Y_min--5.951--------
Intrinsic Value_1Y_max---0.929--------
Intrinsic Value_1Y_min---0.913--------
Intrinsic Value_3Y_max---1.494--------
Intrinsic Value_3Y_min---1.452--------
Intrinsic Value_5Y_max---0.497--------
Intrinsic Value_5Y_min---0.572--------
Market Cap195212436.480-422%1018571317.1201471888811.648-31%1647274388.040-38%959742522.981+6%959742522.981+6%
Net Profit Margin--0.0440.123-65%-39.441+90512%-18.344+42150%-18.344+42150%
Operating Margin--0.0180.094-81%-40.135+225159%-18.506+103874%-18.506+103874%
Operating Ratio--0.9820.906+8%40.633-98%18.967-95%18.967-95%
Pb Ratio0.460-411%2.3503.803-38%7.747-70%3.554-34%3.554-34%
Pe Ratio10.531-411%53.824104.170-48%-8.531+116%29.427+83%29.427+83%
Price Per Share2.880-411%14.72020.985-30%24.303-39%13.935+6%13.935+6%
Price To Free Cash Flow Ratio3.776-411%19.298-22.688+218%-8.894+146%-9.717+150%-9.717+150%
Price To Total Gains Ratio10.864-411%55.526-117.571+312%-12.819+123%-65.195+217%-65.195+217%
Quick Ratio--7.46710.135-26%11.928-37%8.439-12%8.439-12%
Return On Assets--0.0090.027-66%-0.205+2342%-0.335+3762%-0.335+3762%
Return On Equity--0.0110.031-64%-0.244+2339%-0.066+703%-0.066+703%
Total Gains Per Share--0.2650.310-14%1.814-85%0.482-45%0.482-45%
Usd Book Value--433432000.000397711250.000+9%229592500.000+89%156446307.692+177%156446307.692+177%
Usd Book Value Change Per Share--0.2650.310-14%1.814-85%0.482-45%0.482-45%
Usd Book Value Per Share--6.2645.687+10%3.387+85%2.253+178%2.253+178%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0680.176-61%-0.732+1170%-0.280+510%-0.280+510%
Usd Free Cash Flow--13195000.0002669500.000+394%-45599250.000+446%-19685384.615+249%-19685384.615+249%
Usd Free Cash Flow Per Share--0.1910.039+392%-0.673+453%-0.291+252%-0.291+252%
Usd Free Cash Flow To Equity Per Share--0.1940.051+277%1.656-88%0.611-68%0.611-68%
Usd Market Cap195212436.480-422%1018571317.1201471888811.648-31%1647274388.040-38%959742522.981+6%959742522.981+6%
Usd Price Per Share2.880-411%14.72020.985-30%24.303-39%13.935+6%13.935+6%
Usd Profit--4731000.00012317750.000-62%-49593750.000+1148%-18894384.615+499%-18894384.615+499%
Usd Revenue--108449000.00095196500.000+14%5557500.000+1851%31023153.846+250%31023153.846+250%
Usd Total Gains Per Share--0.2650.310-14%1.814-85%0.482-45%0.482-45%
 EOD+4 -4MRQTTM+13 -20YOY+18 -165Y+21 -1310Y+21 -13

4.2. Fundamental Score

Let's check the fundamental score of Amylyx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.531
Price to Book Ratio (EOD)Between0-10.460
Net Profit Margin (MRQ)Greater than00.044
Operating Margin (MRQ)Greater than00.018
Quick Ratio (MRQ)Greater than17.467
Current Ratio (MRQ)Greater than15.664
Debt to Asset Ratio (MRQ)Less than10.162
Debt to Equity Ratio (MRQ)Less than10.194
Return on Equity (MRQ)Greater than0.150.011
Return on Assets (MRQ)Greater than0.050.009
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.526
Ma 20Greater thanMa 507.836
Ma 50Greater thanMa 10012.671
Ma 100Greater thanMa 20013.662
OpenGreater thanClose2.760
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets517,454
Total Liabilities84,022
Total Stockholder Equity433,432
 As reported
Total Liabilities 84,022
Total Stockholder Equity+ 433,432
Total Assets = 517,454

Assets

Total Assets517,454
Total Current Assets464,666
Long-term Assets52,788
Total Current Assets
Cash And Cash Equivalents 170,201
Short-term Investments 201,161
Net Receivables 40,050
Inventory 38,323
Other Current Assets 14,931
Total Current Assets  (as reported)464,666
Total Current Assets  (calculated)464,666
+/-0
Long-term Assets
Property Plant Equipment 6,411
Long-term Assets Other 45,658
Long-term Assets  (as reported)52,788
Long-term Assets  (calculated)52,069
+/- 719

Liabilities & Shareholders' Equity

Total Current Liabilities82,042
Long-term Liabilities1,980
Total Stockholder Equity433,432
Total Current Liabilities
Short-term Debt 2,257
Accounts payable 22,061
Other Current Liabilities 57,724
Total Current Liabilities  (as reported)82,042
Total Current Liabilities  (calculated)82,042
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,980
Long-term Liabilities  (as reported)1,980
Long-term Liabilities  (calculated)1,980
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -304,949
Accumulated Other Comprehensive Income 197
Other Stockholders Equity 738,177
Total Stockholder Equity (as reported)433,432
Total Stockholder Equity (calculated)433,432
+/-0
Other
Capital Stock7
Cash and Short Term Investments 371,362
Common Stock Shares Outstanding 69,196
Liabilities and Stockholders Equity 517,454
Net Debt -165,964
Net Invested Capital 433,432
Net Working Capital 382,624
Property Plant and Equipment Gross 8,039
Short Long Term Debt Total 4,237



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
14,104
0
0
130,460
105,614
274,438
225,240
181,443
391,453
407,958
453,588
466,584
517,454
517,454466,584453,588407,958391,453181,443225,240274,438105,614130,4600014,104
   > Total Current Assets 
13,639
0
0
129,942
101,510
265,488
216,139
171,629
382,133
389,053
427,394
434,110
464,666
464,666434,110427,394389,053382,133171,629216,139265,488101,510129,9420013,639
       Cash And Cash Equivalents 
12,877
0
0
76,677
50,191
110,403
67,440
107,734
62,526
114,563
247,760
135,258
170,201
170,201135,258247,760114,56362,526107,73467,440110,40350,19176,6770012,877
       Short-term Investments 
0
0
0
49,025
45,927
144,802
139,241
54,859
284,419
231,111
109,516
219,787
201,161
201,161219,787109,516231,111284,41954,859139,241144,80245,92749,025000
       Net Receivables 
0
0
0
0
0
0
0
137
15,306
17,855
34,273
29,453
40,050
40,05029,45334,27317,85515,3061370000000
       Other Current Assets 
762
0
0
4,240
5,392
10,283
9,458
8,336
10,113
12,449
10,987
17,238
14,931
14,93117,23810,98712,44910,1138,3369,45810,2835,3924,24000762
   > Long-term Assets 
465
0
0
518
4,104
8,950
9,101
9,814
9,320
18,905
26,194
32,474
52,788
52,78832,47426,19418,9059,3209,8149,1018,9504,10451800465
       Property Plant Equipment 
151
0
0
329
474
8,075
8,226
8,069
8,135
7,647
7,280
6,950
6,411
6,4116,9507,2807,6478,1358,0698,2268,07547432900151
       Other Assets 
314
0
0
0
189
0
9,101
0
0
0
18,914
0
0
0018,9140009,1010189000314
> Total Liabilities 
80,829
0
0
254,530
256,782
33,492
32,451
37,415
50,846
55,310
67,223
48,184
84,022
84,02248,18467,22355,31050,84637,41532,45133,492256,782254,5300080,829
   > Total Current Liabilities 
7,326
0
0
15,146
17,396
27,706
27,164
32,647
46,609
49,523
64,082
45,617
82,042
82,04245,61764,08249,52346,60932,64727,16427,70617,39615,146007,326
       Short-term Debt 
0
0
0
263
0
1,405
1,787
1,990
2,040
2,093
2,146
2,201
2,257
2,2572,2012,1462,0932,0401,9901,7871,4050263000
       Short Long Term Debt 
0
0
0
263
0
0
0
0
0
0
0
0
0
000000000263000
       Accounts payable 
3,613
0
0
3,026
4,372
10,045
8,117
7,052
46,609
10,770
24,695
6,371
22,061
22,0616,37124,69510,77046,6097,0528,11710,0454,3723,026003,613
       Other Current Liabilities 
3,713
0
0
11,857
13,024
16,256
17,260
23,605
-2,040
36,660
37,241
37,045
57,724
57,72437,04537,24136,660-2,04023,60517,26016,25613,02411,857003,713
   > Long-term Liabilities 
73,503
0
0
239,384
239,386
5,786
5,287
4,768
4,237
5,787
3,141
2,567
1,980
1,9802,5673,1415,7874,2374,7685,2875,786239,386239,3840073,503
       Long term Debt 
1,425
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001,425
       Capital Lease Obligations Min Short Term Debt
0
0
0
-263
0
5,786
5,287
4,768
4,237
3,694
3,141
2,567
1,980
1,9802,5673,1413,6944,2374,7685,2875,7860-263000
       Other Liabilities 
16
0
0
0
35
0
7,074
0
0
0
0
0
0
0000007,07403500016
       Long-term Liabilities Other 
0
0
0
0
0
5,786
5,287
4,768
4,237
3,694
0
0
0
0003,6944,2374,7685,2875,78600000
> Total Stockholder Equity
-66,725
0
0
-124,070
-151,168
240,946
192,789
144,028
340,607
352,648
386,365
418,400
433,432
433,432418,400386,365352,648340,607144,028192,789240,946-151,168-124,07000-66,725
   Common Stock
1
0
0
1
1
6
6
6
7
7
7
7
7
7777766611001
   Retained Earnings -304,949-309,680-330,573-352,647-354,220-311,516-257,760-203,693-155,845-127,50100-67,914
   Capital Surplus 
0
0
0
0
0
444,784
450,739
456,263
694,906
705,263
0
0
0
000705,263694,906456,263450,739444,78400000
   Treasury Stock0000000000000
   Other Stockholders Equity 
1,188
0
0
3,431
4,667
170,346
225,499
274,820
694,906
297,305
263,415
261,640
738,177
738,177261,640263,415297,305694,906274,820225,499170,3464,6673,431001,188



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue380,786
Cost of Revenue-25,441
Gross Profit355,345355,345
 
Operating Income (+$)
Gross Profit355,345
Operating Expense-316,543
Operating Income38,80238,802
 
Operating Expense (+$)
Research Development128,187
Selling General Administrative188,356
Selling And Marketing Expenses0
Operating Expense316,543316,543
 
Net Interest Income (+$)
Interest Income16,155
Interest Expense-0
Other Finance Cost-0
Net Interest Income16,155
 
Pretax Income (+$)
Operating Income38,802
Net Interest Income16,155
Other Non-Operating Income Expenses0
Income Before Tax (EBT)54,29739,462
EBIT - interestExpense = 38,802
54,297
49,271
Interest Expense0
Earnings Before Interest and Taxes (EBIT)38,80254,297
Earnings Before Interest and Taxes (EBITDA)39,890
 
After tax Income (+$)
Income Before Tax54,297
Tax Provision-5,026
Net Income From Continuing Ops49,27149,271
Net Income49,271
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses341,984
Total Other Income/Expenses Net-660-16,155
 

Technical Analysis of Amylyx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amylyx. The general trend of Amylyx is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amylyx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amylyx Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 6.51 < 7.645 < 11.82.

The bearish price targets are: 2.7.

Tweet this
Amylyx Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amylyx Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amylyx Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amylyx Pharmaceuticals Inc. The current macd is -3.47628781.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amylyx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Amylyx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Amylyx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Amylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAmylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amylyx Pharmaceuticals Inc. The current adx is 54.21.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Amylyx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Amylyx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amylyx Pharmaceuticals Inc. The current sar is 15.43.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Amylyx Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amylyx Pharmaceuticals Inc. The current rsi is 21.53. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Amylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAmylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amylyx Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amylyx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Amylyx Pharmaceuticals Inc Daily Stochastic Oscillator ChartAmylyx Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amylyx Pharmaceuticals Inc. The current cci is -50.05502554.

Amylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAmylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amylyx Pharmaceuticals Inc. The current cmo is -64.17126939.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Amylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAmylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amylyx Pharmaceuticals Inc. The current willr is -87.79069767.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Amylyx Pharmaceuticals Inc Daily Williams %R ChartAmylyx Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amylyx Pharmaceuticals Inc. The current atr is 0.95064329.

Amylyx Pharmaceuticals Inc Daily Average True Range (ATR) ChartAmylyx Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amylyx Pharmaceuticals Inc. The current obv is -20,085,667.

Amylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAmylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amylyx Pharmaceuticals Inc. The current mfi is 20.20.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAmylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amylyx Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Amylyx Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.526
Ma 20Greater thanMa 507.836
Ma 50Greater thanMa 10012.671
Ma 100Greater thanMa 20013.662
OpenGreater thanClose2.760
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Amylyx with someone you think should read this too:
  • Are you bullish or bearish on Amylyx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Amylyx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Amylyx Pharmaceuticals Inc.

Receive notifications about Amylyx Pharmaceuticals Inc in your mailbox!